PMID- 17698384
OWN - NLM
STAT- MEDLINE
DCOM- 20080408
LR  - 20220410
IS  - 1201-9712 (Print)
IS  - 1201-9712 (Linking)
VI  - 12
IP  - 1
DP  - 2008 Jan
TI  - Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients 
      infected with HBV and untreated with lamivudine.
PG  - 83-7
AB  - OBJECTIVES: A few reports exist on hepatitis B virus (HBV) genotype distribution 
      in Iran; however the sample sizes of these studies are insufficient. The first 
      objective of this study was to determine the HBV genotype distribution with a 
      large sample size (147 specimens). The second objective was to determine the 
      incidence of the lamivudine-resistant YMDD mutant profile among HBV-infected 
      patients not treated with lamivudine; some studies have reported that YMDD 
      mutants are detectable even before antiviral treatment. METHODS: We used two 
      cost-effective PCR-based methods that have been developed in-house: gap-PCR and 
      artificially created restriction site-PCR (ACRS-PCR). Also, 11 samples were 
      randomly selected and bi-directionally sequenced and subjected to phylogenetic 
      analysis. RESULTS: Gap-PCR results revealed genotype D of HBV in all patients, 
      and ACRS-PCR results disclosed the absence of mutation within the YMDD motif 
      before antiviral therapy in the study population. Phylogenetic analysis supported 
      the former genotyping results with the segregation of all Iranian HBV isolates in 
      the genotype D branch with a high bootstrap value (99%, 1000 replicates). 
      CONCLUSIONS: The present study using two cost-effective methods showed that 
      genotype D of HBV is dominant among Iranian HBV-infected subjects, and HBV 
      lamivudine-resistant strains do not exist naturally among Iranian patients not 
      treated with lamivudine.
FAU - Amini-Bavil-Olyaee, Samad
AU  - Amini-Bavil-Olyaee S
AD  - Biotechnology Department, Pasteur Institute of Iran, 13164 Tehran, Iran. 
      samini@ukaachen.de
FAU - Hosseini, Sayed Younes
AU  - Hosseini SY
FAU - Sabahi, Farzaneh
AU  - Sabahi F
FAU - Alavian, Seyed-Moayed
AU  - Alavian SM
LA  - eng
PT  - Journal Article
DEP - 20070814
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the 
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (Gene Products, pol)
RN  - 0 (P protein, Hepatitis B virus)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 2T8Q726O95 (Lamivudine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amino Acid Motifs/drug effects/*genetics
MH  - Drug Resistance, Viral/genetics
MH  - Female
MH  - Gene Products, pol/*genetics
MH  - Genotype
MH  - Hepatitis B virus/classification/drug effects/*genetics
MH  - Hepatitis B, Chronic/epidemiology/*genetics
MH  - Humans
MH  - Iran/epidemiology
MH  - Lamivudine/administration & dosage/*pharmacology
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Phylogeny
MH  - Reverse Transcriptase Inhibitors/administration & dosage/*pharmacology
MH  - Sequence Analysis, DNA
EDAT- 2007/08/19 09:00
MHDA- 2008/04/09 09:00
CRDT- 2007/08/19 09:00
PHST- 2006/10/31 00:00 [received]
PHST- 2007/05/09 00:00 [revised]
PHST- 2007/05/16 00:00 [accepted]
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2008/04/09 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - S1201-9712(07)00111-7 [pii]
AID - 10.1016/j.ijid.2007.05.001 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2008 Jan;12(1):83-7. doi: 10.1016/j.ijid.2007.05.001. Epub 2007 
      Aug 14.